Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a ...
Business Wire3h
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Hosted on MSN3mon
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
royalty-free voluntary licencing agreements with Gilead Sciences Ireland UC to manufacture and distribute the latter's human immunodeficiency virus (HIV) drug Lenacapavir in India and 120 low- and ...
Becker's Hospital Review12d
Gilead, government settle HIV drug patent dispute
Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation ...
pharmaphorum4d
ViiV claims $1.25bn settlement from Gilead in HIV patent dispute
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
U.S. News & World Report13d
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs
Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...